PL3083969T3 - Układ do wytwarzania wektorów wirusowych - Google Patents
Układ do wytwarzania wektorów wirusowychInfo
- Publication number
- PL3083969T3 PL3083969T3 PL14821255T PL14821255T PL3083969T3 PL 3083969 T3 PL3083969 T3 PL 3083969T3 PL 14821255 T PL14821255 T PL 14821255T PL 14821255 T PL14821255 T PL 14821255T PL 3083969 T3 PL3083969 T3 PL 3083969T3
- Authority
- PL
- Poland
- Prior art keywords
- production system
- viral vector
- vector production
- viral
- vector
- Prior art date
Links
- 239000013603 viral vector Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10351—Methods of production or purification of viral material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15041—Use of virus, viral particle or viral elements as a vector
- C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15051—Methods of production or purification of viral material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15051—Methods of production or purification of viral material
- C12N2740/15052—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16041—Use of virus, viral particle or viral elements as a vector
- C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16051—Methods of production or purification of viral material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14151—Methods of production or purification of viral material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/10—Vectors comprising a special translation-regulating system regulates levels of translation
- C12N2840/102—Vectors comprising a special translation-regulating system regulates levels of translation inhibiting translation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/55—Vectors comprising a special translation-regulating system from bacteria
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1322798.8A GB201322798D0 (en) | 2013-12-20 | 2013-12-20 | Production system |
| PCT/GB2014/053813 WO2015092440A1 (en) | 2013-12-20 | 2014-12-19 | Viral vector production system |
| EP14821255.8A EP3083969B1 (en) | 2013-12-20 | 2014-12-19 | Viral vector production system |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3083969T3 true PL3083969T3 (pl) | 2020-03-31 |
Family
ID=50071322
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL14821255T PL3083969T3 (pl) | 2013-12-20 | 2014-12-19 | Układ do wytwarzania wektorów wirusowych |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US10544429B2 (pl) |
| EP (2) | EP3083969B1 (pl) |
| JP (3) | JP6655014B2 (pl) |
| KR (1) | KR102354365B1 (pl) |
| CN (1) | CN106029891B (pl) |
| DK (1) | DK3083969T3 (pl) |
| ES (2) | ES2911805T3 (pl) |
| GB (1) | GB201322798D0 (pl) |
| PL (1) | PL3083969T3 (pl) |
| WO (1) | WO2015092440A1 (pl) |
Families Citing this family (74)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10577627B2 (en) | 2014-06-09 | 2020-03-03 | Voyager Therapeutics, Inc. | Chimeric capsids |
| CN107106689A (zh) | 2014-11-05 | 2017-08-29 | 沃雅戈治疗公司 | 用于治疗帕金森病的aadc多核苷酸 |
| CN112410338A (zh) | 2014-11-14 | 2021-02-26 | 沃雅戈治疗公司 | 调节性多核苷酸 |
| IL292999A (en) | 2014-11-14 | 2022-07-01 | Voyager Therapeutics Inc | Compositions and methods of treating amyotrophic lateral sclerosis (als) |
| WO2016094783A1 (en) | 2014-12-12 | 2016-06-16 | Voyager Therapeutics, Inc. | Compositions and methods for the production of scaav |
| US9777064B2 (en) | 2015-03-17 | 2017-10-03 | Chimera Bioengineering, Inc. | Smart CAR devices, DE CAR polypeptides, side CARs and uses thereof |
| US11052111B2 (en) | 2015-12-08 | 2021-07-06 | Chimera Bioengineering, Inc. | Smart CAR devices and DE CAR polypeptides for treating disease and methods for enhancing immune responses |
| WO2017106202A2 (en) * | 2015-12-14 | 2017-06-22 | The Trustees Of The University Of Pennsylvania | Gene therapy for ocular disorders |
| WO2017189964A2 (en) | 2016-04-29 | 2017-11-02 | Voyager Therapeutics, Inc. | Compositions for the treatment of disease |
| US11326182B2 (en) | 2016-04-29 | 2022-05-10 | Voyager Therapeutics, Inc. | Compositions for the treatment of disease |
| US10222369B2 (en) | 2016-05-17 | 2019-03-05 | Chimera Bioengineering, Inc. | Methods for making novel antigen binding domains |
| KR20220108216A (ko) | 2016-05-18 | 2022-08-02 | 보이저 테라퓨틱스, 인크. | 헌팅톤 질환을 치료하기 위한 조성물 및 방법 |
| SG11201809699XA (en) | 2016-05-18 | 2018-12-28 | Voyager Therapeutics Inc | Modulatory polynucleotides |
| CN110650673B (zh) | 2016-08-30 | 2024-04-09 | 加利福尼亚大学董事会 | 用于生物医学靶向和递送的方法以及用于实践该方法的装置和系统 |
| EP4342978A3 (en) | 2016-09-01 | 2024-07-03 | Chimera Bioengineering Inc. | Gold optimized car t-cells |
| WO2018060097A1 (en) * | 2016-09-30 | 2018-04-05 | Laboratorios Del Dr. Esteve, S. A. | Adenoassociated virus vectors for the treatment of mucopolysaccharidoses |
| CN110022904B (zh) | 2016-10-20 | 2024-04-19 | 桑格摩生物治疗股份有限公司 | 用于治疗法布里病的方法和组合物 |
| WO2018102064A1 (en) | 2016-11-30 | 2018-06-07 | Microsoft Technology Licensing, Llc. | Dna random access storage system via ligation |
| US10793897B2 (en) * | 2017-02-08 | 2020-10-06 | Microsoft Technology Licensing, Llc | Primer and payload design for retrieval of stored polynucleotides |
| EP4389894A3 (en) * | 2017-03-10 | 2024-08-28 | The Medical College of Wisconsin, Inc. | Riboswitch modulated gene therapy for retinal diseases |
| AU2018235130B2 (en) | 2017-03-15 | 2023-12-07 | Oxford Biomedica (Uk) Limited | Method |
| GB201706121D0 (en) * | 2017-04-18 | 2017-05-31 | Glaxosmithkline Ip Dev Ltd | Stable cell lines for retroviral production |
| SG11201909870SA (en) | 2017-05-05 | 2019-11-28 | Voyager Therapeutics Inc | Compositions and methods of treating amyotrophic lateral sclerosis (als) |
| JP2020518259A (ja) | 2017-05-05 | 2020-06-25 | ボイジャー セラピューティクス インコーポレイテッドＶｏｙａｇｅｒ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． | ハンチントン病治療組成物および方法 |
| WO2018209216A1 (en) | 2017-05-12 | 2018-11-15 | University Of Massachusetts | Viral vector production |
| US11827898B2 (en) | 2017-06-14 | 2023-11-28 | The Trustees Of The University Of Pennsylvania | Gene therapy for ocular disorders |
| JOP20190269A1 (ar) | 2017-06-15 | 2019-11-20 | Voyager Therapeutics Inc | بولي نوكليوتيدات aadc لعلاج مرض باركنسون |
| JP7229989B2 (ja) | 2017-07-17 | 2023-02-28 | ボイジャー セラピューティクス インコーポレイテッド | 軌道アレイガイドシステム |
| US20210130775A1 (en) * | 2017-08-02 | 2021-05-06 | Autolus Limited | Cells expressing a chimeric antigen receptor or engineered tcr and comprising a nucleotide sequence which is selectively expressed |
| MX2020003042A (es) | 2017-09-29 | 2020-11-18 | Voyager Therapeutics Inc | Rescate del fenotipo neurológico central y periférico de la ataxia de friedreich mediante administración intravenosa. |
| US11485957B2 (en) | 2017-10-10 | 2022-11-01 | Nantbio, Inc. | Modified EC7 cells having low toxicity to viral production payloads |
| EP4454654A3 (en) | 2017-10-16 | 2025-02-19 | Voyager Therapeutics, Inc. | Treatment of amyotrophic lateral sclerosis (als) |
| US11434502B2 (en) | 2017-10-16 | 2022-09-06 | Voyager Therapeutics, Inc. | Treatment of amyotrophic lateral sclerosis (ALS) |
| EP3696272A1 (en) | 2017-12-22 | 2020-08-19 | Oxford BioMedica (UK) Limited | Retroviral vector |
| CN111989108B (zh) | 2018-02-13 | 2024-07-16 | 嵌合体生物工程公司 | 利用rna去稳定元件协调基因表达 |
| CN113056561A (zh) * | 2018-04-05 | 2021-06-29 | 牛津大学科技创新有限公司 | 用于治疗黄斑营养不良的组合物和方法 |
| EP3794126A1 (en) | 2018-05-15 | 2021-03-24 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of parkinson's disease |
| GB201807945D0 (en) * | 2018-05-16 | 2018-06-27 | Ospedale San Raffaele Srl | Vector production |
| CA3110563A1 (en) * | 2018-08-31 | 2020-03-05 | University Of Florida Research Foundation, Incorporated | Adeno-associated viral vectors for the treatment of best disease |
| CN113383010B (zh) | 2018-09-28 | 2025-09-09 | 沃雅戈治疗公司 | 具有经工程化改造的启动子的共济蛋白表达构建体及其使用方法 |
| PH12021551619A1 (en) * | 2019-01-06 | 2022-05-23 | Abintus Bio Inc | Car t cell methods and constructs |
| MX2021008832A (es) | 2019-02-08 | 2021-09-08 | Krystal Biotech Inc | Composiciones y metodos para la administracion de polipeptidos cftr. |
| US20220348958A1 (en) * | 2019-07-23 | 2022-11-03 | Oxford Biomedica (Uk) Limited | Enhancing Production of Lentiviral Vectors |
| EP4013431A4 (en) | 2019-08-18 | 2024-05-01 | Chimera Bioengineering, Inc. | Combination therapy with gold controlled transgenes |
| KR20210026024A (ko) | 2019-08-29 | 2021-03-10 | 변정원 | 학습에 대한 보상을 제공하여 동기부여를 높이는 학습 보조 어플리케이션 |
| CN114901297A (zh) * | 2019-10-16 | 2022-08-12 | 卡利威尔免疫治疗公司 | 用于原位产生逆转录病毒的生产者病毒 |
| KR20220097492A (ko) | 2019-11-12 | 2022-07-07 | 옥스포드 바이오메디카(유케이) 리미티드 | 생산 시스템 |
| JP2023513303A (ja) * | 2020-02-13 | 2023-03-30 | オックスフォード バイオメディカ（ユーケー）リミテッド | レンチウイルスベクターの製造 |
| US20230133201A1 (en) * | 2020-03-11 | 2023-05-04 | Remotor Therapeutics, Inc. | Methods and materials for disseminating a protein throughout the central nervous system |
| US20230118587A1 (en) | 2020-03-13 | 2023-04-20 | Oxford Biomedica (Uk) Limited | Lentiviral Vectors |
| GB202007199D0 (en) | 2020-05-15 | 2020-07-01 | Oxford Biomedica Ltd | Viral vector production |
| CN113699112A (zh) * | 2020-05-20 | 2021-11-26 | 苏州方德门达新药开发有限公司 | 表达重组hsv-1 us11蛋白的工程细胞及其在提高慢病毒包装效率中的应用 |
| CA3180301A1 (en) * | 2020-05-26 | 2021-12-02 | Otto J. Prohaska | Devices and methods for transfection |
| GB202017725D0 (en) | 2020-11-10 | 2020-12-23 | Oxford Biomedica Ltd | Method |
| CN112430582B (zh) * | 2020-12-04 | 2022-05-03 | 北京艺妙神州医药科技有限公司 | 一种慢病毒稳定包装细胞系及其制备方法 |
| CN112501210B (zh) * | 2020-12-07 | 2022-08-05 | 和元生物技术（上海）股份有限公司 | 外源基因可控表达的慢病毒包装方法 |
| GB202102832D0 (en) * | 2021-02-26 | 2021-04-14 | Ip2Ipo Innovations Ltd | Retroviral vectors |
| WO2023056194A2 (en) | 2021-09-29 | 2023-04-06 | Chimera Bioengineering, Inc. | Compositions and methods for anti-tnmuc1 gold car t-cells |
| GB202114534D0 (en) | 2021-10-12 | 2021-11-24 | Oxford Biomedica Ltd | Novel viral regulatory elements |
| GB202114532D0 (en) | 2021-10-12 | 2021-11-24 | Oxford Biomedica Ltd | Lentiviral Vectors |
| GB202114528D0 (en) | 2021-10-12 | 2021-11-24 | Oxford Biomedica Ltd | Lentiviral vectors |
| GB202114529D0 (en) | 2021-10-12 | 2021-11-24 | Oxford Biomedica Ltd | Lentiviral vectors |
| GB202114530D0 (en) | 2021-10-12 | 2021-11-24 | Oxford Biomedica Ltd | Retroviral vectors |
| US12234472B2 (en) | 2021-10-18 | 2025-02-25 | Regeneron Pharmaceuticals, Inc. | Eukaryotic cells comprising adenovirus-associated virus polynucleotides |
| CN114181972A (zh) * | 2021-11-23 | 2022-03-15 | 上海本导基因技术有限公司 | 适用于难治性血管新生性眼疾病基因治疗的慢病毒载体 |
| CN114107231B (zh) * | 2021-12-13 | 2023-08-18 | 重庆大学 | 实现全脑突触后神经元胞体标记的重组腺相关病毒及其应用 |
| CN114639442B (zh) * | 2022-03-30 | 2024-01-30 | 中国农业科学院农业基因组研究所 | 一种基于单核苷酸多态性预测开放阅读框的方法及系统 |
| CN119365208A (zh) | 2022-04-13 | 2025-01-24 | 巴塞罗那自治大学 | 通过表达klotho蛋白的基因疗法治疗神经肌肉疾病 |
| CN115161345A (zh) * | 2022-06-14 | 2022-10-11 | 同宜医药（苏州）有限公司 | 高表达FRα的重组载体、重组细胞及其构建方法和用途 |
| GB202211935D0 (en) | 2022-08-16 | 2022-09-28 | Oxford Biomedica Ltd | envelope proteins |
| WO2024081352A2 (en) * | 2022-10-12 | 2024-04-18 | University Of Kansas | Third-generation lentiviral gene therapy rescues function in a mouse model of usher ib |
| WO2024151704A2 (en) * | 2023-01-10 | 2024-07-18 | Sana Biotechnology, Inc. | Process for viral vector production |
| CN116621947B (zh) * | 2023-07-18 | 2023-11-07 | 北京智源人工智能研究院 | 一种基于索烃骨架的拓扑蛋白质、制备方法及应用 |
| WO2025153852A1 (en) * | 2024-01-17 | 2025-07-24 | 1. Revvity Gene Delivery Gmbh | Production of viral vectors |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4797368A (en) | 1985-03-15 | 1989-01-10 | The United States Of America As Represented By The Department Of Health And Human Services | Adeno-associated virus as eukaryotic expression vector |
| US5139941A (en) | 1985-10-31 | 1992-08-18 | University Of Florida Research Foundation, Inc. | AAV transduction vectors |
| US5512421A (en) | 1991-02-19 | 1996-04-30 | The Regents Of The University Of California | Generation, concentration and efficient transfer of VSV-G pseudotyped retroviral vectors |
| CA2199832C (en) | 1994-09-19 | 2000-08-01 | Philippe Leboulch | Anti-sickling beta-globin protein, compositions and methods for treating sickle cell disease |
| GB9510272D0 (en) | 1995-05-22 | 1995-07-19 | Isis Innovation | Retroviral vectors |
| US5723315A (en) | 1996-08-23 | 1998-03-03 | Genetics Institute, Inc. | Secreted proteins and polynucleotides encoding them |
| US6100071A (en) | 1996-05-07 | 2000-08-08 | Genentech, Inc. | Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production |
| PT968182E (pt) | 1996-08-07 | 2004-08-31 | Darwin Discovery Ltd | Derivados de acidos hidroxamicos e carboxilicos com actividade inibidora da mpm e do fnt |
| US6126939A (en) | 1996-09-03 | 2000-10-03 | Yeda Research And Development Co. Ltd. | Anti-inflammatory dipeptide and pharmaceutical composition thereof |
| GB2325003B (en) | 1996-10-17 | 2000-05-10 | Oxford Biomedica Ltd | Rectroviral vectors |
| US6924123B2 (en) | 1996-10-29 | 2005-08-02 | Oxford Biomedica (Uk) Limited | Lentiviral LTR-deleted vector |
| JP2001519143A (ja) | 1997-10-02 | 2001-10-23 | スノル・モレキュラー・コーポレーション | 可溶性の一本鎖ｔ細胞レセプタータンパク質 |
| ATE528405T1 (de) | 1997-12-22 | 2011-10-15 | Oxford Biomedica Ltd | Auf dem virus der infektiösen pferdeanämie (eiav) basierende vektoren |
| GB9803351D0 (en) | 1998-02-17 | 1998-04-15 | Oxford Biomedica Ltd | Anti-viral vectors |
| AU4924199A (en) * | 1998-07-30 | 2000-02-21 | Advec, Inc. | Repressor proteins producing cell lines for the propagation of vectors |
| GB9904905D0 (en) | 1999-03-03 | 1999-04-28 | Oxford Biomedica Ltd | Cells |
| GB0009760D0 (en) | 2000-04-19 | 2000-06-07 | Oxford Biomedica Ltd | Method |
| MXPA04001974A (es) | 2001-08-31 | 2004-07-16 | Avidex Ltd | Receptor de celula t soluble. |
| DK1504108T3 (da) | 2002-02-01 | 2013-06-10 | Oxford Biomedica Ltd | Lentivirusvektor |
| FR2872170B1 (fr) | 2004-06-25 | 2006-11-10 | Centre Nat Rech Scient Cnrse | Lentivirus non interactif et non replicatif, preparation et utilisations |
| GB0526211D0 (en) | 2005-12-22 | 2006-02-01 | Oxford Biomedica Ltd | Viral vectors |
| GB0526210D0 (en) * | 2005-12-22 | 2006-02-01 | Oxford Biomedica Ltd | Vectors |
| WO2009153563A1 (en) | 2008-06-18 | 2009-12-23 | Oxford Biomedica (Uk) Limited | Virus purification |
| EP2432794B1 (en) * | 2009-05-22 | 2017-08-30 | The Research Foundation of State University of New York | Trans-acting rna switches |
| GB201118636D0 (en) | 2011-10-28 | 2011-12-07 | Oxford Biomedica Ltd | Nucleotide sequence |
| JP2015529466A (ja) | 2012-09-14 | 2015-10-08 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 鎌状赤血球症の幹細胞遺伝子治療のためのレンチウイルスベクター |
-
2013
- 2013-12-20 GB GBGB1322798.8A patent/GB201322798D0/en not_active Ceased
-
2014
- 2014-12-19 EP EP14821255.8A patent/EP3083969B1/en active Active
- 2014-12-19 JP JP2016541089A patent/JP6655014B2/ja active Active
- 2014-12-19 EP EP19190116.4A patent/EP3650548B1/en active Active
- 2014-12-19 ES ES19190116T patent/ES2911805T3/es active Active
- 2014-12-19 WO PCT/GB2014/053813 patent/WO2015092440A1/en not_active Ceased
- 2014-12-19 PL PL14821255T patent/PL3083969T3/pl unknown
- 2014-12-19 US US15/106,555 patent/US10544429B2/en active Active
- 2014-12-19 KR KR1020167019013A patent/KR102354365B1/ko active Active
- 2014-12-19 ES ES14821255T patent/ES2748377T3/es active Active
- 2014-12-19 DK DK14821255.8T patent/DK3083969T3/da active
- 2014-12-19 CN CN201480076100.0A patent/CN106029891B/zh active Active
-
2019
- 2019-12-13 US US16/714,516 patent/US12054735B2/en active Active
-
2020
- 2020-01-31 JP JP2020014654A patent/JP7340471B6/ja active Active
-
2022
- 2022-04-07 JP JP2022064011A patent/JP2022091989A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP3650548A1 (en) | 2020-05-13 |
| WO2015092440A1 (en) | 2015-06-25 |
| CN106029891B (zh) | 2021-09-07 |
| GB201322798D0 (en) | 2014-02-05 |
| KR102354365B1 (ko) | 2022-01-20 |
| JP2020096609A (ja) | 2020-06-25 |
| JP6655014B2 (ja) | 2020-02-26 |
| US12054735B2 (en) | 2024-08-06 |
| EP3083969A1 (en) | 2016-10-26 |
| ES2911805T3 (es) | 2022-05-20 |
| ES2748377T3 (es) | 2020-03-16 |
| DK3083969T3 (da) | 2019-10-14 |
| EP3650548B1 (en) | 2022-03-09 |
| US10544429B2 (en) | 2020-01-28 |
| EP3083969B1 (en) | 2019-08-07 |
| KR20160122125A (ko) | 2016-10-21 |
| US20160333373A1 (en) | 2016-11-17 |
| JP7340471B6 (ja) | 2024-02-26 |
| CN106029891A (zh) | 2016-10-12 |
| US20200102578A1 (en) | 2020-04-02 |
| JP2022091989A (ja) | 2022-06-21 |
| JP2017500870A (ja) | 2017-01-12 |
| JP7340471B2 (ja) | 2023-09-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GB201322798D0 (en) | Production system | |
| GB201313153D0 (en) | Merchant system | |
| GB201301576D0 (en) | System | |
| GB201312991D0 (en) | Process | |
| GB201310432D0 (en) | Virus Production | |
| GB201316940D0 (en) | Tranaction system | |
| GB201307334D0 (en) | Process | |
| GB201304819D0 (en) | Suspension system | |
| GB201316269D0 (en) | Process | |
| GB201318888D0 (en) | Process | |
| IL240916A0 (en) | Bromo-indirubins-5 | |
| GB201313915D0 (en) | Process | |
| SG11201603919XA (en) | Viral vector manufacture | |
| GB201314334D0 (en) | Process | |
| GB201307951D0 (en) | Process | |
| GB201302441D0 (en) | Process | |
| GB201312899D0 (en) | Isolated networking system | |
| GB201316253D0 (en) | Process | |
| GB201300073D0 (en) | Process | |
| GB2517013B (en) | Facing system | |
| GB201314561D0 (en) | Process | |
| GB2526222B (en) | Viral peptides | |
| GB201318175D0 (en) | Process | |
| AU2013904242A0 (en) | Viral vector manufacture | |
| AU2013903985A0 (en) | Viral vector manufacture |